Humana Inc. Reaffirms Earnings Guidance for FY 2026
Key Points:
- Humana Inc. (NYSE: HUM) has filed a Form 8-K with the SEC, reporting upcoming investor and analyst meetings scheduled between June 1 and June 30, 2026.
- During these meetings, Humana intends to reaffirm its earnings guidance for the full year ending December 31, 2026:
- At least \$8.36 in diluted earnings per common share (EPS, GAAP)
- At least \$9.00 in adjusted earnings per common share (Adjusted EPS, non-GAAP)
- This guidance is consistent with Humana’s previous press release issued on April 29, 2026.
- Humana provides a reconciliation between GAAP EPS and Adjusted EPS:
- GAAP EPS: At least \$8.36
- Adjustments:
- Amortization of identifiable intangibles: + \$0.30
- Put/call valuation adjustments (non-consolidating minority interest investments): – \$0.28
- Value creation initiatives: + \$0.81
- Cumulative net tax impact: – \$0.19
- Resulting in Adjusted (non-GAAP) EPS: At least \$9.00
- Humana management uses Adjusted (non-GAAP) EPS as a metric for evaluating core operating performance, planning, and incentive compensation decisions.
- The Company expects potential changes to its GAAP EPS guidance due to ongoing value creation and other strategic initiatives but does not expect changes to its Adjusted EPS guidance.
Implications for Shareholders and Investors:
- The reaffirmed guidance provides clarity and stability regarding Humana’s expected financial performance for FY 2026.
- Maintaining Adjusted EPS guidance at \$9.00 signals management’s confidence in core business operations and underlying earnings power.
- Any changes to GAAP EPS are anticipated to arise from strategic initiatives, which may include acquisitions, investments, or restructuring activities. These could impact reported earnings but are not expected to affect the company’s adjusted earnings outlook.
- The guidance, if viewed positively by the market, may support Humana’s share price by reinforcing management’s commitment to delivering value and transparency to shareholders.
- Investors should monitor upcoming investor and analyst meetings for additional commentary or updates, as these events are often catalysts for share price movement, especially if new material information is disclosed.
- The Company expressly cautions that forward-looking statements are subject to risks, uncertainties, and assumptions, including factors detailed in Humana’s SEC filings under “Risk Factors.”
Other Notable Information:
- Humana’s common stock trades on the New York Stock Exchange under the ticker symbol HUM.
- The company is not classified as an emerging growth company, and there are no amendments or pre-commencement tender offers disclosed in this filing.
Disclaimer:
This article is based on Humana Inc.’s Form 8-K filed with the SEC on June 1, 2026. The information provided herein contains forward-looking statements, which are subject to risks and uncertainties. Investors should review Humana’s official filings and consult with financial advisors before making investment decisions. This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
